Forward Management’s Teva Pharmaceuticals TEVA Stock Holding History

Forward Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-81,830	Closed	-$4.33M	–	302
2015 Q2	$4.33M	Sell	81,830 -17,725	-18%	-$1.09M	0.27%	59
2015 Q1	$5.21M	Buy	99,555 +5,435	+6%	+$316K	0.31%	56
2014 Q4	$4.79M	Sell	94,120 -16,465	-15%	-$917K	0.26%	61
2014 Q3	$5.68M	Buy	110,585 +37,680	+52%	+$2M	0.34%	51
2014 Q2	$3.7M	Buy	72,905 +5,135	+8%	+$262K	0.21%	65
2014 Q1	$3.4M	Buy	+67,770	New	+$3.13M	0.2%	70

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Forward Management's TEVA Position: Q3 2015 in Review

Forward Management sold out of Teva Pharmaceuticals (TEVA) in Q3 2015, closing a stake of 81,830 shares — an estimated $4.33M sold.

Forward Management first reported a position in TEVA in Q1 2014 and held it in 6 quarters. The position peaked at $5.68M in Q3 2014. 823 funds tracked by Wall St. Rank hold TEVA as of Q3 2015.

Forward Management reported no remaining Teva Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
Forward Management sold 81,830 Teva Pharmaceuticals shares in Q3 2015, an estimated $4.33M.
Forward Management first reported a position in Teva Pharmaceuticals in Q1 2014 and held it in 6 quarters.
Forward Management's Teva Pharmaceuticals position peaked at $5.68M in Q3 2014.
823 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2015.

Based on Forward Management's 13F filing for Q3 2015, filed 9 Nov 2015.